Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Global $11.2 Billion Biologics Contract Development Market to 2027


DUBLIN, Sept. 25, 2020 /PRNewswire/ -- The "Biologics Contract Development Market Size, Share & Trends Analysis Report by Source (Mammalian, Microbial), by Product Service Type, by Disease Indication (Oncology, Immunological Disorders), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global biologics contract development market size is expected to reach USD 11.2 billion by 2027, expanding at a CAGR of 8.8% over the forecast period.

The market comprises of organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications including drug screening, gene functional studies, and biologics production.

Factors such as increasing adoption of advanced technologies for biologic development, favorable environment for clinical trials in developing countries, and an increase in outsourcing of R&D activities are paving way for the growth of the market.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and amalgamation of advanced and specialized technologies. For instance, in February 2020, LakePharma, Inc., and NJ Biopharmaceuticals LLC, a CRO, providing integrated chemistry and biology services, announced a strategic alliance to offer streamlined Antibody-Drug Conjugate (ADC) development solutions for biotechnology and pharmaceutical sectors.

Many biopharma and pharma companies are increasingly looking for outsourcing their activities as it helps accelerate workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development and manufacturing organization market growth in the coming years.

Biologics Contract Development Market Report Highlights

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing adoption of advanced technologies
3.2.3 Increasing mergers and collaborations
3.2.4 Favourable environment for clinical trials in developing countries
3.2.5 Increasing outsourcing of R&D activities
3.2.6 Market Restraint Analysis
3.2.7 Intellectual property rights issues
3.3 Penetration & Growth Prospect Mapping
3.4 Biologics Contract Development: Market Analysis Tools
3.4.1 Industry Analysis-Porter's
3.4.2 PESTEL Analysis

Chapter 4 Biologics Contract Development Market: Source Type Segment Analysis
4.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
4.1.1 Microbial
4.1.2 Mammalian
4.1.3 Others

Chapter 5 Biologics Contract Development Market: Product Service Segment Analysis
5.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
5.2 Cell Line Development
5.2.1 Cell Line Development Market, 2016-2027 (USD Million)
5.2.1.1 Microbial Cell Line Development
5.2.1.2 Mammalian Cell Line Development
5.2.1.3 Others
5.2.1.3.1 Others Market, 2016-2027 (USD Million)
5.3 Process Development
5.3.1 Process Development Market, 2016-2027 (USD Million)
5.3.2 Upstream Process Development
5.3.2.1 Upstream Process Development Market, 2016-2027 (USD Million)
5.3.2.1.1 Microbial
5.3.2.1.2 Microbial Market, 2016-2027 (USD Million)
5.3.2.1.3 Mammalian
5.3.2.1.4 Mammalian Market, 2016-2027 (USD Million)
5.3.2.1.5 Others
5.3.3 Downstream Process Development
5.3.3.1 Downstream Process Development, 2016-2027 (USD Million)
5.3.3.1.1 Impurity, Isolation, & Identification
5.3.3.1.3 Physicochemical Characterization
5.3.3.1.4 Physicochemical Characterization Market, 2016-2027 (USD Million)
5.3.3.1.5 Pharmaceutical Analysis
5.3.3.1.6 Pharmaceutical Analysis Market, 2016-2027 (USD Million)
5.3.3.1.7 Others
5.4 Downstream Process, By Product
5.4.1 Mabs (Monoclonal Antibodies)
5.4.2 Recombinant Proteins
5.4.2.1 Recombinant Proteins Analysis Market, 2016-2027 (USD Million)
5.4.2.1.1 Others
5.5 Other Product Service (Quality and Regulatory Services, Etc)

Chapter 6 Biologics Contract Development Market: Disease Indication Segment Analysis
6.1 Biologics Contract Development Market: Market Share Analysis, 2019 & 2027
6.2 Oncology
6.3 Immunological Disorders
6.4 Cardiovascular Disorders
6.5 Haematological Disorders

Chapter 7 Biologics Contract Development Market: Regional Analysis

Chapter 8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/vyqo4z

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 22:33
Corventive Health, a provider of cloud-based and AI technology solutions, announced a partnership with Halfpenny Technologies, an Accumen, Inc. company today. This partnership fortifies Corventive's core capability of delivering clinical insights...

at 22:03
Alterity Therapeutics ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States....

at 20:39
Trusted health and lifestyle expert, Dr. Yael Varnado gives advice for fall health and wellness. Dr. V is a practicing physician. STAYING WELL Taking better care of ourselves can be as easy as swapping out a light bulb. Choosing the right lighting...

at 20:10
Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of...

at 20:00
Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, today announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma") as well as...

at 19:35
EdiGene, Inc. ( "Company", or "EdiGene"), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted for review the Company's Investigational New Drug (IND) application for ET-01,...



News published on 25 september 2020 at 12:15 and distributed by: